sulted in a greater decline in eGFR. The annual eGFR decline rates were -1.89, -1.29, and -0.68 ml/min/1.73 m 2 /year for baseline HbA 1C >9, 7 to ≤ 9, and ≤ 7%, respectively. The eGFR value was simultaneously affected by concurrent (β coefficient = 0.78, 95% CI: 0.48-1.08, p < 0.0001) and preceding HbA 1C (-0.52, -0.82 to -0.23, p < 0.0001). The positive effects of concurrent HbA 1C on eGFR reached statistical significance at all stages of chronic kidney disease (CKD); however, the negative effects of preceding HbA 1C only applied to CKD stages 3 and 4. Conclusions: We developed a new model that demonstrates how preceding and concurrent HbA 1C simultaneously affect eGFR in opposing ways. The dynamic effects varied among different CKD stages. The deterioration in eGFR at CKD stages 3 and 4 may be postponed by intensive glycemic control. Further prospective studies may be necessary to clarify the specific CKD stage(s) that will benefit from intensive glycemic control.
creasing levels of glycated hemoglobin (HbA 1C ) [2] . The UK Prospective Diabetes Study (UKPDS) demonstrated that intensive glycemic control decreased the risk of microvascular complications [3] .The Diabetes Control and Complications Trial (DCCT) further proved that intensive glycemic control reduced the incidence of microalbuminuria in patients with type 1 diabetes mellitus (DM) [4] . Likewise, in the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified-Release Controlled Evaluation (ADVANCE) study, intensive glucose control resulted in a reduction in renal events [5] . Although the benefits of glycemic control, such as renal protection, have been widely and consistently reported, previous investigations have primarily focused on delaying the development of microalbuminuria. Intensive diabetic therapy was only recently shown to be associated with a slower reduction in glomerular filtration rate (GFR) than conventional therapy in type 1 DM patients via the longterm follow-up of the Epidemiology of Diabetes Interventions and Complications (EDIC) study [6] . However, the effects of intensive glycemic control on the preservation of GFR in type 2 DM patients remain unclear.
A previous cross-sectional study in early type 1 DM patients demonstrated that HbA 1C positively correlated with GFR [7] . This positive correlation existed not only in early type 1 DM, but also in type 2 DM patients [8] .
Conversely, results from a longitudinal observational study demonstrated that higher baseline HbA 1C resulted in a more rapid GFR decline [9] . These seemingly opposing correlations suggest that the actual relationship between HbA 1C and GFR cannot be explained by a simple linear model. Additionally, the positive correlation between concurrent HbA 1C and GFR also raised the question of how glycemic status alters renal function. Thus far, no literature has provided an ideal model to account for the inconsistent relationship between HbA 1C and GFR. To clarify these issues, this study aims to establish a model that explains the controversial effects of HbA 1C on GFR via cross-sectional and longitudinal analyses.
Methods

Study Population
This retrospective cohort study was performed by physicians at a medical center in central Taiwan. [8] . Although CKD-EPI (Epidemiology Collaboration) is more accurate than the MDRD equation for subjects with eGFR >60 ml/min/1.73 m 2 , the MDRD formula was applied in the Taiwan National Database to evaluate dialysis initiation and CKD prevalence [10] [11] [12] . Subjects whose baseline eGFR was >180 ml/min/1.73 m 2 were excluded. This study was approved by the Human Research Review Committee of the Taichung Veterans General Hospital.
Study Design
The design of this study was divided into the following sequential parts. First, we examined the positive correlation between HbA 1C and eGFR using a cross-sectional analysis. Then, the negative correlation between HbA 1C and future GFR values was identified, and the annual eGFR decline was calculated to represent the rate of renal impairment over time. If HbA 1C was negatively correlated with future eGFR, then it may be assumed that a higher baseline HbA 1C may cause a greater annual eGFR decline in subsequent years. If HbA 1C was positively correlated with eGFR in the cross-sectional analysis but negatively correlated with future eGFR, then it may be deduced that the impact of HbA 1C on eGFR varies with time. Lastly, we investigated the possibility that the two opposite effects may coexist, and how renal function status may interfere with these effects.
Statistical Analyses
Descriptive statistics for continuous variables are expressed as means and standard deviations. All reported p values were two sided and considered significant when p < 0.05. Additionally, 95% confidence intervals are reported. For the correlation between HbA 1C values and eGFR in the cross-sectional analysis, the fixed effect model analysis was used, with baseline eGFR as the dependent variable, to determine the individual related variables with univariate linear regression analysis. The variables that significantly contributed to baseline eGFR in univariate analysis were used in multivariate analysis. Due to the collinearity between age and eGFR, age by decades was used instead. For the effects of HbA 1C on future eGFR, we used a mixed model repeated measures (MMRM) to evaluate the eGFR decline rate according to different levels of baseline HbA 1C . Each eGFR was set as the dependent variable, whereas time was set as the independent variable. Changes in the annual eGFR were defined as the β coefficient of time in MMRM. Baseline HbA 1C 1C were assigned as independent variables. Preceding eGFR, time, and gender were adjusted as covariates. Analyses were also performed separately according to baseline CKD stages. CKD stages 1, 2, 3, 4, and 5 were defined as baseline eGFR ≥ 90, 60-89.99, 30-59.99, 15-29.99, and <15 ml/min/1.73 m 2 , respectively. Statistical analyses were performed using the Statistical Package for Social Sciences (version 15.0; SPSS Inc., Chicago, Ill., USA).
Results
Of the total 1,992 subjects that were enrolled, 1,699 completed the follow-up. Table 1 summarizes the baseline characteristics of the subjects that were included in the study. Their mean age was 66.1 years, and the mean baseline HbA 1C was 8.1%. Over the 4-year follow-up period, the mean HbA 1C levels were 8.1, 7.9, 7.7, and 7.7% (p for trend <0.0001). The mean number of OADs was 1.4. At baseline, 18.8% of the subjects were on insulin. The mean eGFR at baseline was 62.1 ml/min/1.73 m 2 , which then decreased to 59.5, 57.6, 57.9, and 56.9 ml/min/1.73 m 2 in the following 4 years (p for trend <0.0001).
The results of fixed effect model analyses, with eGFR as a dependent variable, are shown in table 2 . In univariate analysis, gender, age (by decade), HbA 1C , number of OAD, insulin usage, use of antihypertensive medication, SBP, and DBP were associated with baseline eGFR. There was no correlation between hyperlipidemic medication and baseline eGFR. However, due to the possible confounding effects of hyperlipidemic treatment, this variable was also used in multivariate analysis [13, 14] . In multivariate analysis, the effects of SBP and DBP on baseline eGFR were no longer significant due to collinearity with antihypertensive medications. Meanwhile, age (by decade), number of OAD, and use of antihypertensive medication still correlated with baseline eGFR in multivariate analysis. As expected, baseline HbA 1C positively correlated with baseline eGFR, both in univariate and multivariate models. Furthermore, this correlation was still present with the HbA 1C and eGFR values for the following years. The adjusted β coefficient of HbA 1C for eGFR was 1.59 (p < 0.001), 1.60 (p < 0.001), 1.72 (p < 0.001), and 1.70 (p < 0.001) for years 1, 2, 3, and 4, respectively.
The crude and adjusted annual mean changes in eGFR are presented in table 3 . In regard to the significant interactions, only time by HbA 1C and time by eGFR reached statistical significance. However, the difference in the annual mean changes in eGFR between genders did not reach statistical significance (p = 0.791). Stratified analysis was then performed according to the HbA 1C and eGFR categories. The annual mean change in eGFR did differ between the HbA 1C and eGFR categories. The adjusted annual decline in eGFR was -1.90 (ml/min/1.73 m 2 /year), -1.46, and -0.85, for baseline HbA 1C >9%, 7% < HbA 1C ≤ 9%, and HbA 1C ≤ 7%, respectively. The adjusted annual changes in eGFR were -2.56 and -0.78 ml/min/1.73 m 2 / year for baseline eGFR ≥ 60 and <60 ml/min/1.73 m 2 , respectively. Higher baseline HbA 1C and eGFR were both associated with more rapid annual eGFR decline. We also used a new category combining both baseline HbA 1C and eGFR status. In subjects with baseline eGFR ≥ 60 ml/ min/1.73 m Table 4 summarizes the dynamic effect of HbA 1C on eGFR at different time points, as determined via MMRM. Current HbA 1C was found to be positively correlated with eGFR, whereas preceding HbA 1C was found to be negatively correlated with eGFR. The dual effects of concurrent and preceding HbA 1C on eGFR, according to CKD stages, are presented in figure 1 . Concurrent HbA 1C was positively correlated with eGFR at all CKD stages. In contrast, preceding HbA 1C was negatively correlated with eGFR in the next year, although differences were only statistically significant at CKD stages 3 and 4. Except CKD stages, different time of preceding HbA 1C was further analyzed using a dynamic model. The adjusted β coefficient of preceding HbA 1C was -0.52 (p < 0.001), -0.51 (p = 0.002), -0.54 (p = 0.005), and -0.34 (p = 0.209) for the preceding 1, 2, 3, and 4 years (data not shown).
Discussion
The present study revealed that HbA 1C was positively correlated with eGFR via a cross-sectional analysis. A higher baseline HbA 1C and higher eGFR resulted in a greater decline in eGFR. Furthermore, preceding HbA 1C had a negative effect on eGFR, whereas concurrent HbA 1C had a positive effect on eGFR. The dynamic and dual effects of preceding and concurrent HbA 1C on eGFR also varied among different CKD stages.
Cross-Sectional Relationship between HbA 1C and eGFR
Using the fixed effect model, HbA 1C was positively correlated with eGFR. Previous studies showed that hyperglycemia increased GFR in subjects with impaired fasting glucose [16] . Similar studies also showed that GFR was significantly correlated with HbA 1C , both in early type 1 and 2 DM subjects [7, 8] . Thus, these reports were in accordance with our findings.
Longitudinal Relationship between HbA 1C and eGFR
We demonstrated that a higher baseline HbA 1C results in a greater decline in eGFR. This trend was more obvious in those with eGFR ≥ 60 ml/min/1.73 m 2 or UAER >300 mg/ g creatinine. In a longitudinal study on type 1 diabetics with nephropathy, there was a positive correlation between HbA 1C and the decline in GFR [17] .
Additionally, we reported that subjects with baseline eGFR ≥ 60 ml/min/1.73 m 2 had greater eGFR decline rates than those with baseline eGFR <60 ml/min/1.73 m 2 . Comparable prospective studies in type 2 DM patients indicated that there was a significant relationship be- MMRM analyses, with eGFR as the dependent variable, were performed for the total population and at each CKD stage. The impact of concurrent and preceding HbA 1C on eGFR were estimated with the β coefficient (β) after adjusting for preceding eGFR, time, and gender. tween baseline GFR and changes in GFR [18] . A previous meta-analysis of type 1 DM patients similarly suggested that those with higher baseline GFR tend to develop diabetic nephropathy [19] . Considering the effects of both baseline HbA 1C and eGFR status on eGFR decline, the best way to determine the accurate influence of these on eGFR was to combine the two effects together. Using this new classification, we demonstrated that the rate of eGFR decline had a dose-dependent relationship with baseline HbA 1C and eGFR status. Subjects with the most preserved renal function and worst glycemic control presented with the fastest rate of eGFR decline. Those who had the worst renal function, but best glycemic control, presented with the slowest rate of eGFR decline; however, this was not statistically significant. This may be due to the limited size of our study population.
Dynamic Association between HbA 1C and eGFR
To the best of our knowledge, this longitudinal study is the first to examine the dynamic and dual effects of HbA 1C on eGFR which reflected true clinical conditions. In our dynamic model, the effects of HbA 1C on eGFR rely on the 'tug of war' between concurrent and preceding HbA 1C . At each CKD stage, concurrent HbA 1C had a significantly positive effect on eGFR. Moreover, this positive effect was the most apparent in CKD stage 1. This is compatible with the glomerular hyperfiltration present in early DM [20] . Conversely, preceding HbA 1C had a negative effect on eGFR. Although the negative effects of preceding HbA 1C on eGFR were seen at each CKD stage, statistical significance was only apparent at CKD stages 3 and 4. This finding suggests that poor glycemic control precipitated the deterioration in eGFR in those at CKD stages 3 and 4. It also suggests that intensive glycemic control may effectively postpone the deterioration in eGFR at these two CKD stages. In fact, the negative effects of preceding HbA 1C actually surpassed the positive effects of concurrent HbA 1C at CKD stage 3 ( table 4 ) . Therefore, our findings suggest that CKD stage 3 may be the critical stage for delaying eGFR deterioration with intensive glycemic control.
The dynamic and dual effects of concurrent and preceding HbA 1C varied among CKD stages. This finding also reflects the pathophysiology of DM nephropathy. The significantly positive effects of concurrent HbA 1C on eGFR at all CKD stages imply that hyperfiltration existed at each CKD stage, but primarily at stage 1. It is well known that hyperglycemia increases glomerular hyperfiltration by raising the ultrafiltration coefficient and increasing membrane permeability to small dextrans [21] .
Additionally, hyperglycemia causes excess deposition of extracellular proteins, mesangial cell expansion by upregulating growth factors, gradual glomerular sclerosis, and, finally, decreased GFR [22] . The decrease in GFR induced by hyperglycemia through multiple factors is consistent with the negative impact of preceding HbA 1C on eGFR in our study. Our findings suggest that hyperglycemia may cause glomerular hyperfiltration during earlier rather than later stages of CKD. At CKD stages 3 and 4, poor glycemic control results in increased deposition of extracellular proteins. Thus, in the later stages of CKD, the negative impact of hyperglycemia on GFR becomes more dominant. At CKD stage 5, when glomerular sclerosis is most severe and little renal function remains, the renalprotective effects of intensive glycemic control become less obvious. The classic five stages of nephropathy were previously described by Mogensen et al. [23] . Microalbuminuria plays an important role in this staging system, and adequate glycemic control reduces the development of microalbuminuria [24] . Our study proposed that, at CKD stages 3 and 4, there may be another critical point for delaying the progression of DM nephropathy using strict glycemic control.
In the ACCORD (Action to Control Cardiovascular Risk in Diabetes) study, intensive glycemic control did not reveal any improvements in serum creatinine [25] . In the VADT (Veterans Affairs Diabetes Trial), there were no benefits of intensive glycemic control on the rate of GFR decline [26] . In the DCCT study, there were no differences in the slopes of creatinine clearance between intensive and conventional glycemic control [27] . However, in the EDIC study, intensive diabetic therapy resulted in a slower eGFR decline than conventional therapy [6] . In the UKPDS study, intensive glycemic control resulted in a significant reduction in the proportion of doubling serum creatinine [24] . With the exception of differences in age, study population, or follow-up duration, the dynamic and dual effects of HbA 1C may offer another explanation for the controversial findings among the abovementioned studies. Since HbA 1C at different time points had opposing effects on eGFR, the net effect of HbA 1C on eGFR should be the sum of the impact of both preceding and concurrent HbA 1C . Therefore, certain studies may fail to observe the direct benefits of good glycemic control on improving GFR. Additionally, the opposing dual effects of HbA 1C varied among the different CKD stages. This may cause more heterogeneous results among studies if the study populations are not stratified according to the CKD stages. The dynamic model can apply not only to heterogeneous effects among CKD stages, but also to the memory effect of HbA 1C . The negative effects of preceding HbA 1C on eGFR reached statistical significance from preceding years 1-3. In the DCCT trial, HbA 1c from preceding years 2-3 were associated with the greatest relative risk of contributing to current retinopathy [28] . Although studying different diabetic complications, our findings revealed a similar time effect of preceding HbA 1C in accordance with the DCCT trial. However, we lack sufficient data to show the effect of HbA 1C levels before the preceding 4 years on renal function.
Clinical Implications
Based on our study findings, we recommend maintaining HbA 1C ≤ 7% for renal protection in type 2 DM subjects. This may transiently decrease the eGFR due to a correction in hyperfiltration, similar to newly diagnosed DM patients [29] . In the long-term, however, proper glycemic control will provide better renal protection by improving the rate of eGFR decline. In our study, HbA 1C increasers presented more rapid annual eGFR decline than HbA 1C decreasers, though no statistically significant difference was reached. This finding also supports maintaining HbA 1C ≤ 7% for eGFR preservation.
The strengths of this study include recruitment from a clinical practice, a regular longitudinal follow-up, a large sample size, and the new concept of dynamic and dual effects of HbA 1C on eGFR. However, the following limitations of this study should be mentioned. First, HbA 1C variability was not examined in this study, although it was reported as an independent predictor of nephropathy [30] . Second, although we adjusted for baseline covariates that may affect GFR, we did not annually collect all potential covariates, such as variations in blood pressure or changes in medication. This may cause some bias in the estimations. Despite these limitations, different models from cross-sectional, longitudinal, and dynamic analyses revealed a consistent relationship between HbA 1C and eGFR. Therefore, we consider our findings robust.
In conclusion, we provided a new model which suggests that preceding and concurrent HbA 1C dynamically affect eGFR in opposing ways. The deterioration in eGFR at CKD stages 3 and 4 may be postponed by intensive glycemic control. Further well-designed, prospective studies are needed to further specify the CKD stages that will actually benefit from intensive glycemic control.
